ThinkEquity Upgrades ViroPharma (VPHM) to Buy
More News related to VPHM
- Personalized Pharmaceutical Systems Announces Sale of Angioedema Clinical Prediction Guide to Viropharma Incorporated
- ViroPharma to Present at Three November Healthcare Conferences
- ThinkEquity Upgrades ViroPharma (VPHM) to Buy
- Trading Radar for 10/28: First Solar (FSLR), ConocoPhillips (COP), WellPoint (WLP), Goodyear (GT), Int. Paper (IP) Report
- Morning Movers 10/28: CSBC, QTM, ANIK, RSYS, PEET, WSII Higher; CALC, KSP, PSYS, VCLK, VPHM, GT Lower
ThinkEquity upgrades ViroPharma (Nasdaq: VPHM) from Source of Funds to Buy.
To see more analyst ratings on VPHM Click Here.
ViroPharma Incorporated, a biopharmaceutical company, engages in the development and commercialization of products that address serious diseases with a focus on products used by physician specialists or in hospital settings in the United States and internationally.
Related Categories
UpgradesStocks Mentioned
+0.25Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
